Dongcheng Pharmaceutical: Application for Marketing Authorization of Mosatamide Mesylate for Injection Accepted
Dongcheng Pharmaceutical's subsidiary, Yantai Dongcheng Northern Pharmaceutical, has received acceptance for its marketing authorization application for injectable nafamostat mesylate. This drug already has similar products available internationally and one domestic first-copy generic on the market. Sales data indicates that injectable nafamostat mesylate generated 442 million yuan in sales in hospitals above Grade II during the first three quarters of 2025. AI